SELLAS Life Sciences Group, Inc.
(NASDAQ : SLS)

( )
SLS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.37%171.931.3%$497.00m
BIIBBiogen Inc.
-0.44%234.001.3%$478.23m
CELGCelgene Corporation
-0.61%95.771.3%$454.43m
GILDGilead Sciences, Inc.
0.57%66.880.9%$437.21m
ILMNIllumina, Inc.
2.08%312.833.5%$317.70m
REGNRegeneron Pharmaceuticals, Inc.
-0.81%317.502.6%$296.20m
AAgilent Technologies, Inc.
-0.02%67.971.6%$207.65m
VRTXVertex Pharmaceuticals Incorporated
1.92%172.371.9%$181.17m
EXASExact Sciences Corporation
0.56%95.4425.3%$164.58m
ALXNAlexion Pharmaceuticals, Inc.
-0.97%127.552.0%$149.64m
BMRNBioMarin Pharmaceutical Inc.
0.25%87.694.3%$118.55m
SRPTSarepta Therapeutics, Inc.
-1.74%119.5014.7%$110.19m
INCYIncyte Corporation
0.43%79.022.5%$105.72m
IONSIonis Pharmaceuticals, Inc.
-0.82%68.008.2%$97.93m
ALNYAlnylam Pharmaceuticals, Inc
-0.84%67.249.2%$94.14m

Company Profile

SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutics for cancer indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. Its products include galinpepimut-S and nelipepimut-S. The company was founded on April 3, 2006 and is headquartered in New York, NY.